

## A novel RUNX1 exon 3 - 7 deletion causing a familial platelet disorder

Almazni, Ibrahim Abdullah F; Chudakou, Pavel; Dawson-Meadows, Alison; Downes, Kate; Freson, Kathleen; Mason, Joanne; Page, Paula; Reay, Kim; Myers, Bethan; Morgan, Neil

DOI:

[10.1080/09537104.2021.1887470](https://doi.org/10.1080/09537104.2021.1887470)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Almazni, IAF, Chudakou, P, Dawson-Meadows, A, Downes, K, Freson, K, Mason, J, Page, P, Reay, K, Myers, B & Morgan, N 2021, 'A novel RUNX1 exon 3 - 7 deletion causing a familial platelet disorder', *Platelets*.  
<https://doi.org/10.1080/09537104.2021.1887470>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

This is an Accepted Manuscript version of the following article, accepted for publication in *Platelets*. Ibrahim Almazni, Pavel Chudakou, Alison Dawson-Meadows, Kate Downes, Kathleen Freson, Joanne Mason, Paula Page, Kim Reay, Bethan Myers & Neil V Morgan (2021) A novel RUNX1 exon 3 - 7 deletion causing a familial platelet disorder, *Platelets*, DOI: 10.1080/09537104.2021.1887470. It is deposited under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.



**A novel RUNX1 exon 3 - 7 deletion causing a familial platelet disorder**

Journal:	<i>Platelets</i>
Manuscript ID	CPLA-2020-0580.R1
Manuscript Type:	Case Report
Date Submitted by the Author:	29-Jan-2021
Complete List of Authors:	Almazni, Ibrahim; University of Birmingham Chudakou, Pavel; Lincoln County Hospital Dawson-Meadows, Alison; Lincoln County Hospital Downes, Kate; East Genomic Laboratory Hub Freson, Kathleen; KU Leuven, Cardiovascular Sciences Mason, Joanne; West Midlands Regional Genetics Laboratory Page, Paula; West Midlands Regional Genetics Laboratory Reay, Kim; West Midlands Regional Genetics Laboratory Myers, Bethan; University Hospitals of Leicester NHS Trust, Haemostasis and Thrombosis Morgan, Neil; University of Birmingham,
Keywords:	RUNX1, thrombocytopenia, platelet disorder, NGS, CNV, bleeding

SCHOLARONE™  
Manuscripts

1  
2  
3 **A novel *RUNX1* exon 3 - 7 deletion causing a familial platelet disorder**  
4  
5  
6

7 Ibrahim Almazni<sup>1</sup>, Pavel Chudakou<sup>2</sup>, Alison Dawson-Meadows<sup>2</sup>, Kate Downes<sup>3</sup>, Kathleen Freson<sup>4</sup>,  
8 Joanne Mason<sup>5</sup>, Paula Page<sup>5</sup>, Kim Reay<sup>5</sup>, Bethan Myers<sup>2,6</sup>, Neil V Morgan<sup>1\*</sup> on behalf of the UK  
9 GAPP Study Group  
10  
11

12  
13  
14 <sup>1</sup>Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of  
15 Birmingham, Birmingham, UK  
16

17  
18 <sup>2</sup>Department of Haematology, Lincoln County Hospital, Lincoln, UK  
19

20 <sup>3</sup>East Genomic Laboratory Hub, Cambridge University Hospitals, Cambridge, UK  
21

22 <sup>4</sup>Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of  
23 Leuven, Leuven, Belgium  
24

25  
26 <sup>5</sup>West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital, Birmingham, UK  
27

28 <sup>6</sup>Department of Haematology, University Hospitals of Leicester, Leicester, UK  
29  
30  
31  
32

33 **Running title:** *RUNX1* deletion and platelet disorder  
34  
35  
36

37 **Corresponding author**  
38

39 \* Dr Neil Morgan, Institute of Cardiovascular Sciences, College of Medical and Dental  
40 Sciences, Edgbaston, University of Birmingham, Birmingham, B15 2TT, UK; E-mail:  
41 [N.V.Morgan@bham.ac.uk](mailto:N.V.Morgan@bham.ac.uk); Tel +44 (0)121 414 6820.  
42  
43  
44  
45

46 **Word count:** Text: 1087  
47

48 Tables 1, Figures 1  
49

50 References 17  
51  
52  
53  
54  
55

56  
57 **Keywords:** *RUNX1*, thrombocytopenia, platelet disorder, NGS, CNV, bleeding  
58  
59  
60

## Abstract

Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) is a rare inherited disorder confirmed with the presence of a pathogenic germline *RUNX1* variant and is thought to be heavily underdiagnosed. *RUNX1* has also been found to be mutated in up to 10% of adult AML cases and other cell malignancies. We performed targeted next generation sequencing and subsequent MLPA analysis in a kindred with multiple affected individuals with low platelet counts and a bleeding history. We detected a novel heterozygous exon 3 – 7 large deletion in the *RUNX1* gene in all affected family members which is predicted to remove all of the Runt-homology DNA-binding domain and a portion of the the Activation domain. Our results show that the combination of targetted NGS and MLPA analysis is an effective way to detect copy number variants (CNVs) which would be missed by conventional sequencing methods. This precise diagnosis offers the possiblility of accurate counselling and clinical management in such pateints whom could go onto develop other cell malignancies.

## Introduction

Inherited thrombocytopenias (ITs) comprise a heterogeneous group of disorders with a sustained reduction in platelet count which often manifest as a bleeding diathesis. To date 26 forms of IT have been reported with known disease associations in 30 genes which makes genetic diagnosis challenging<sup>1-3</sup>. A precise genetic diagnosis provides clinical benefits for the patients where some patients with IT have unnecessary procedures and treatments such as splenectomies or mistaken for idiopathic thrombocytopenic purpura (ITP) which may be treated with steroids or immunosuppressive drugs with many side effects. Some of the gene variants in IT patients e.g. *RUNX1* result in patients having a predisposition to haematological malignancies and once a genetic defect is proven the information can be used to monitor the patients' haematological parameters more closely. Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) (OMIM# 601399) is confirmed with the presence of a pathogenic germline mutation in *RUNX1*. *RUNX1* variants have been reported in approximately 10% of adult AML, which are mainly

1  
2  
3 acquired but can also be germline and thought to be underdiagnosed<sup>4</sup>. This highlights the need for  
4  
5 a definitive genetic diagnosis to aid clinical management of the condition.  
6

7 Current Next Generation Sequencing (NGS) technologies allow the detection of both point  
8  
9 mutations and CNVs with a single platform and workflow<sup>5-7</sup>. In this study we describe and elucidate  
10  
11 the genetic basis of a single family with 3 affected individuals who suffer from a bleeding diathesis  
12  
13 and low platelet counts with previously unknown genetic diagnosis.  
14  
15

## 16 17 18 **Cases**

19  
20 The family presented here has 3 affected individuals, all with a strong family history of clinical  
21  
22 bleeding including epistaxis and easy bruising associated with low platelet counts and recruited to  
23  
24 the UK Genotyping and Phenotyping of Platelets (GAPP) study<sup>8</sup> (Figure 1A). The index case (P1)  
25  
26 was a 67 year old male when initially recruited to the GAPP study with a 10 year history of a  
27  
28 'probable' hereditary platelet disorder. He had a history of bleeding episodes which included  
29  
30 epistaxis, cutaneous bleeding, bleeding from minor wounds, GI bleeding, oral cavity bleeding,  
31  
32 bleeding after tooth extraction and muscle hematomas. He bled excessively after a hip  
33  
34 replacement. He had a platelet count of  $129 \times 10^9/L$  and mean platelet volume (MPV) of 10.2 fL.  
35  
36 He had Coronary artery bypass graft surgery aged 69 following which he suffered a  
37  
38 thromboembolic stroke.  
39

40  
41 His relatives P2 and P3 (son and grandson respectively) were also referred for genetic testing to  
42  
43 the GAPP study. P2 is a 44 year old man with a clinical history of life-long muco-cutaneous  
44  
45 bleeding. He had a platelet count of  $83 \times 10^9/L$  and MPV of 9.3 fL. P3 is 22 years old with clinical  
46  
47 features of platelet dysfunction. His platelet count at testing was  $96 \times 10^9/L$  and MPV of 12.6 fL.  
48  
49 (Table 1). To date no evidence of AML or other associated haematological malignancies have  
50  
51 been reported in any of these patients. All other haematological parameters were within normal  
52  
53 ranges.  
54

55  
56  
57  
58 The index case P1 was subjected to the ThromboGenomics targeted sequencing platform  
59  
60 (TGv3.0)<sup>5</sup> where CNVs are called using an experimental pipeline based on ExomeDepth<sup>9</sup> version

1  
2  
3 1.1.10. This detected a novel heterozygous CNV Deletion of *RUNX1* from exons 3 – 7 (Figure 1B).  
4  
5 The genetic variant was scored with strong evidence of pathogenicity based on the current ACMG  
6  
7 guidelines<sup>10</sup> (PM2 - Absent from controls (or at extremely low frequency if recessive) in Exome  
8  
9 Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium, PVS1 - Null  
10  
11 variant (nonsense, frameshift, canonical  $\pm 1$  or 2 splice sites, initiation codon, single or multiexon  
12  
13 deletion) in a gene where LOF is a known mechanism of disease). To confirm if the *RUNX1* CNV  
14  
15 deletion was present in all affected patients, Multiplex ligation-dependent probe amplification  
16  
17 (MLPA) analysis was performed which includes all exons of the  
18  
19 *RUNX1/CEBPA/GATA2/TERC/TERT* genes (MRC Holland kit P437-B1), and can detect both  
20  
21 deletions and duplications. The index patient P1 and relatives P2 and P3 were all confirmed to  
22  
23 have the heterozygous *RUNX1* exon 3 – 7 deletion by MLPA analysis (Figure 1C). The deletion  
24  
25 removes 870bp of the mRNA sequence of *RUNX1* which is in frame, but completely removes the  
26  
27 DNA/Runt DNA binding domain and part of the activation domain (Figure 1D).  
28  
29  
30  
31

## 32 Discussion

33  
34 This report describes a family with an inherited thrombocytopenia and history of excessive  
35  
36 bleeding. FPDMM is confirmed in this family studied with the presence of a pathogenic germline  
37  
38 *RUNX1* mutation<sup>11-13</sup>. To date more than 70 FPDMM families have been reported with a 40%  
39  
40 lifetime risk of developing MDS and/or AML<sup>14</sup>. While the majority of familial cases reported in the  
41  
42 literature with *RUNX1* mutations are point mutations, different extended deletions have also been  
43  
44 described<sup>5, 11, 15, 16</sup> (Figure 1D). Here using targeted NGS and subsequent CNV/MLPA analysis, we  
45  
46 have detected a novel heterozygous deletion covering exons 3 – 7 of the *RUNX1* gene which is  
47  
48 predicted to remove the entire DNA Runt/DNA binding domain. *RUNX1/AML1* encodes the DNA  
49  
50 binding unit of the heterodimeric core binding factor (CBF) that is a critical regulator of definitive  
51  
52 hematopoiesis<sup>17</sup>. *RUNX1* is also recurrently mutated gene in sporadic myelodysplastic syndrome  
53  
54 and leukaemia. In sporadic AML, mutations in *RUNX1* are usually secondary events, whereas in  
55  
56 FPDMM they are initiating events. None of the patients included in this study have developed AML  
57  
58 as a result of a secondary somatic event occurring within *RUNX1* to date. It is thought that *RUNX1*  
59  
60

1  
2  
3 variants causing haploinsufficiency are thought to be associated with a lower incidence of myeloid  
4 malignancies when compared to those patients with dominant negative *RUNX1* defects. However  
5  
6  
7 the detection of a *RUNX1* variant in such patients with low platelet counts allows the possibility of  
8  
9 accurate counselling and clinical management for both them and extended family members at 50%  
10  
11 risk of inheriting the pathogenic variant, whom could go onto develop other cell malignancies.  
12  
13  
14

15  
16 **Acknowledgments** The authors would like to thank the family and patients for taking part in the  
17  
18 study. The work in the author's laboratories is supported by the British Heart Foundation  
19  
20 (PG/13/36/30275; FS/15/18/31317; PG/16/103/32650; FS/18/11/33443; NVM) and the Saudi  
21  
22 Arabia Cultural Bureau in London (IA).  
23  
24  
25

26  
27 **Authorship contribution** NVM designed the study; BM recruited the patients; IA, PC, AD-M, KD,  
28  
29 KR, BM and NVM extracted or generated clinical or experimental data; IA, KD, KF, JM, PP, KR  
30  
31 and NVM interpreted the results; KD, and NVM undertook governance of the study; BM and NVM  
32  
33 wrote the manuscript; all authors read and approved the final version of the manuscript.  
34  
35  
36

37  
38  
39 **Disclosure of Conflicts of Interest** The authors report no conflicts of interest  
40

#### 41 **Supplementary Acknowledgements**

42  
43 The members of the UK Genotyping and Phenotyping of Platelets Study Group are: Neil Morgan,  
44 Steve Watson, Gillian Lowe, Paul Harrison, Marie Lordkipanidze (University of Birmingham);  
45 Andrew D Mumford and Stuart J Mundell (University of Bristol); Paul Gissen (University College  
46 London); Martina E. Daly (University of Sheffield); Will Lester and Justin Clark (Birmingham  
47 Women's Hospital); Mike Williams, Jayashree Motwani, Dianne Marshall, Natalie Lawson, Priscilla  
48 Nyatanga, Pat Mann, and Julie Kirwan (Birmingham Children's Hospital); Will Lester, Charles  
49 Percy, Pam Green, Helen Hupston, Koomaravel Nagapachetty, Elizabeth Dwenger, Ann O  
50 Rourke, Martin Pope, Camillia Edmead and April Greenway (University Hospital Birmingham);  
51 Michael Makris (Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital);  
52 Jeanette Payne (Paediatric Haematology Centre, Sheffield Children's Hospital); Sue Pavord,  
53 Richard Gooding and Rashesh Dattani (University Hospitals Leicester); Gerry Dolan Charlotte  
54 Grimley, Simone Stokley, Emma Astwood, Karyn Longmuir, Cherry Chang, Merri Foros, Michelle  
55 Kightley and Linda Trower (Nottingham University Hospitals); Jecko Thachil (previously Paula  
56 Bolton Maggs), Charlie Hay, Gill Pike, Andrew Will, John Grainger, Matt Foulkes, and Mona Fareh  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(Central Manchester National Health Service Foundation Trust); Kate Talks, Tina Biss, Patrick Kesteven, John Hanley, Julie Vowles, Lesley Basey, Kevin Knaggs and Michelle Barnes (Newcastle upon Tyne Hospitals NHS Trust); Peter Collins, Rachel Rayment, Raza Alikhan, Ana Guerrero Rebecca Morris, and Dianne Mansell (Cardiff and Vale University Local Health Board); Cheng Hock Toh and Vanessa Martlew (Royal Liverpool University Hospitals); Elaine Murphy and Robin Lachmann (University College London Hospitals NHS Trust); Peter Rose, Oliver Chapman, Anand Lokare, Kathryn Marshall, and Naseem Khan (University Hospitals Coventry and Warwickshire); David Keeling, Nikki Curry and Paul Giangrande (Oxford Radcliffe Hospitals NHS Trust); Steve Austin, David Bevan and Jayanthi Alamelu (Guys' and St. Thomas' NHS Foundation Trust); David Allsup, Andrew Fletcher, Katherine Gladstone, Jeanette Fenwick, Philippa Woods and Darren Camp (Hull and East Yorkshire Hospitals NHS trust, Castle Hill Hospital, Hull); Beki James, Suzie Preston, Collette Spencer, Alexandra Pike and Chung Lai-Wah (Leeds Teaching Hospitals NHS trust); Angela Thomas (Royal Hospital for Sick Children Edinburgh); Bethan Myers (Lincoln County Hospital); Gillian Evans, Kim Elliot, Karen Davies, Charlotte Graham and Miranda Foad, (Kent Canterbury Hospital), Jacqueline Smith (The Dudley Group NHS Foundation Trust). Dr Neil Morgan has authorised authorship on behalf of the UK Genotyping and Phenotyping of Platelets Study Group.

## References


- 1 Almazni I, Stapley R, Morgan NV. Inherited Thrombocytopenia: Update on Genes and Genetic Variants Which may be Associated With Bleeding. *Front Cardiovasc Med.* 2019; 6: 80.
- 2 Johnson B, Doak R, Allsup D, et al. A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia. *Res Pract Thromb Haemost.* 2018; 2: 640-52.
- 3 Johnson B, Fletcher SJ, Morgan NV. Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan. *Platelets.* 2016; 27: 519-25.
- 4 Simon L, Spinella JF, Yao CY, et al. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. *Blood.* 2020; 135: 1882-6.
- 5 Downes K, Megy K, Duarte D, et al. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. *Blood.* 2019; 134: 2082-91.
- 6 Almazni I, Stapley RJ, Khan AO, Morgan NV. A comprehensive bioinformatic analysis of 126 patients with an inherited platelet disorder to identify both sequence and copy number genetic variants. *Hum Mutat.* 2020; 41: 1848-65.
- 7 Lentaigne C, Freson K, Laffan MA, et al. Inherited platelet disorders: toward DNA-based diagnosis. *Blood.* 2016; 127: 2814-23.
- 8 Watson SP, Lowe GC, Lordkipanidze M, et al. Genotyping and phenotyping of platelet function disorders. *J Thromb Haemost.* 2013; 11 Suppl 1: 351-63.
- 9 Plagnol V, Curtis J, Epstein M, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. *Bioinformatics.* 2012; 28: 2747-54.
- 10 Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015; 17: 405-24.
- 11 Morgan NV, Daly ME. Gene of the issue: RUNX1 mutations and inherited bleeding. *Platelets.* 2017; 28: 208-10.
- 12 Preudhomme C, Renneville A, Bourdon V, et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. *Blood.* 2009; 113: 5583-7.
- 13 Stockley J, Morgan NV, Bem D, et al. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. *Blood.* 2013; 122: 4090-3.
- 14 Liew E, Owen C. Familial myelodysplastic syndromes: a review of the literature. *Haematologica.* 2011; 96: 1536-42.
- 15 Owen CJ, Toze CL, Koochin A, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. *Blood.* 2008; 112: 4639-45.
- 16 Latger-Cannard V, Philippe C, Bouquet A, et al. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. *Orphanet J Rare Dis.* 2016; 11: 49.
- 17 Okuda T, Nishimura M, Nakao M, Fujita Y. RUNX1/AML1: a central player in hematopoiesis. *Int J Hematol.* 2001; 74: 252-7.

**Table 1.** Results of haematological analysis in patients P1-P3 at time of recruitment

Laboratory analysis	P1	P2	P3	Normal range
Haemoglobin	14.0 g/dL	14.3	14.2	13.5 - 17.5
MCV	91.8 fl	90.6	93.8	80.0 - 94.0
Haematocrit	40.5 %	40.5	40.7	41.0 - 53
Red cell count	$4.41 \times 10^{12}/L$	4.47	4.34	3.8 - 6.5
White cell count	$5.37 \times 10^9/L$	6.26	5.08	4.8 - 10.8
Neutrophils	$3.71 \times 10^9$ (69.1 %)/L	$3.38 \times 10^9$ (54.0%)/L	$2.27 \times 10^9$ (44.7%)/L	1.5 - 6.5
Lymphocytes	$0.77 \times 10^9$ (14.3%)/L	$1.68 \times 10^9$ (26.8%)/L	$1.39 \times 10^9$ (27.4%)/L	1.2 - 3.4
Monocytes	$0.68 \times 10^9$ (12.7%)/L	$0.67 \times 10^9$ (10.7%)/L	$0.91 \times 10^9$ (17.9%)/L	0.2 - 0.8
Eosinophils	$0.20 \times 10^9$ (3.7%)/L	$0.52 \times 10^9$ (8.3%)/L	$0.49 \times 10^9$ (9.6%)/L	0 - 0.4
Basophils	$0.01 \times 10^9$ (0.2%)/L	$0.01 \times 10^9$ (0.2%)/L	$0.02 \times 10^9$ (0.4%)/L	0 - 0.1
Platelets	$129 \times 10^9/L$	$83 \times 10^9/L$	$96 \times 10^9/L$	147 - 327
Mean platelet volume	10.2 fl	9.3	12.6	7.8 - 12.69
Immature platelet fraction	5.4%	2.3	13.6	1.3 - 10.8
Reticulocytes	$67.0 \times 10^9/L$ (1.52%)	$91.6 \times 10^9/L$ (2.05%)	$81.6 \times 10^9/L$ (1.88%)	20 - 80 (0.2 - 2%)

## Figure legend

**Figure 1. Identification of a novel germline mutation in RUNX1 in a family with inherited thrombocytopenia** (A) Pedigree of family showing affected individuals (shaded) and platelet counts (B) CNV analysis of sequencing data of P1 using ExomeDepth within the ThromboGenomics targeted sequencing platform, detected a novel heterozygous CNV deletion of *RUNX1* spanning from exons 3 – 7. (C) MLPA analysis detects the heterozygous exon 3 -7 deletion in *RUNX1* in all patients (representative data shown from P1 only). MLPA peak ratios for kit P437-B1 including *RUNX1* (red and green) and control (blue) MLPA test probes (left hand panel). Table shows *RUNX1* exon number or intron (int), bin size and peak ratios. Red, probes with peak ratios <0.75 indicate a heterozygous deletion (grey shaded) (right hand panel). (D) Schematic showing the location of the novel exon 3 – 7 exons deleted within *RUNX1* which are implicated in the FPD/AML family studied. The Runt-homology DNA-binding domain (RHD) spanning amino acids 77 to 204 and the Activation domain (TAD) spanning from amino acid 269 to 438 is also displayed. Alterations are numbered according to positions in the NM\_001754.4 transcript for *RUNX1* (*RUNX1c* isoform). Positions of different types of published *RUNX1* variants causing FPDMM are also shown where *RUNX1* missense variants are almost exclusively located in the Runt homology DNA-binding domain. Reported gross deletions are shown with solid lines and a gross duplication with dashed line.



594x419mm (72 x 72 DPI)